Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Issues in Oncology
Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement




Oct
02
Today In Oncology
Sunvozertinib in Platinum-Pretreated NSCLC With EGFR Exon 20 Insertion Mutations
In Extensive-Stage Small Cell Lung Cancer Novel Maintenance Regimen Boosts Overall Survival
Kidney Cancer Cases Expected to Double by 2050
CT-Adapative SBRT for Recurrent Retroperitoneal Sarcomas
Variation in PSA Levels in Annual Testing Among Individuals Without Prostate Cancer Diagnosis
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo